Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06205771
Enrolling by invitation Not applicable

The Role and Mechanism of GPER-Hippo-CBS/H2S Pathway in Preeclampsia

NCT06205771 · tracked via the Priya Life Science China tracker
Sponsor
Hao Feng
Phase
Not applicable
Started
2024-04-10
Last updated
2024-04-10

Condition(s) studied

Preeclampsia

Investigational drug(s) / intervention(s)

H2S content

H2S content: H2S content

Study summary

The goal of this clinical trial is to learn about in health conditions. The main questions it aims to answer are:

* The pathological significance of GPER in uterine artery dilation in preeclampsia
* The Mechanism of GPER Hippo Pathway Regulating CBS/H2S in Human Uterine Artery Smooth Muscle Cells (hUASMC) This project intends to use GPER interfering RNA, YAP1 interfering RNA, in vivo perfusion experiments of human uterine artery tissue, and single cell patch clamp technology to study hypotheses under physiological/pathological pregnancy conditions at the tissue, cellular, and molecular levels, revealing a novel signal transduction pathway of estrogen stimulating vasodilation, providing new ideas for studying the mechanism of uterine artery blood flow regulation. This research result will provide new targets for intervention and treatment of diseases such as fetal intrauterine growth retardation and preeclampsia.

Eligibility

Sex
FEMALE
Min age
—
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Full term pregnancy with clinical diagnosis of preeclampsia and normal pregnancy pregnant woman 2. Pregnant women undergoing lower segment cesarean section for delivery Exclusion Criteria: 1. Combined with chronic hypertension, kidney disease, intrahepatic cholestasis, etc Other basic diseases; 2. Multiple pregnancy 3. Pregnant women undergoing vaginal delivery 4. Normal pregnant women who are\<37 weeks or\>40 weeks pregnant

Primary outcome measure(s)

  • H2S content in uterine arterial smooth muscle circulation — 8:00 am
    H2S content in circulation

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Shandong First Medical University &Shandong Provincial Qianfoshan Hospital Jinan Please Select

Other trials for the same condition

A Multicenter Cohort Study on Maternal and Infant Microecology and New Targets for Pre-eclampsia Screening in China Recruiting
The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center Recruiting
Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia Starting soon
Aspirin 150 mg vs 100 mg for Prevention of Preeclampsia in High-Risk Obese Pregnant Women Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06205771 on ClinicalTrials.gov ↗ ← All trials in China